BIO-key International Inc. BKYI
1.79
(0.25)
(12.25%)
as of 25 Sep
- Market cap
- $2.9M
- P/E
- 0.0×
Follow BKYI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.75 | 0.60 | 0.85 | 0.70 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.22) | (1.96) | (15.32) | (5.53) | |
P/B ratio |
0.78 | 0.70 | 1.12 | 1.08 | |
Price to Tangible BV |
0.92 | 0.84 | 1.33 | 1.29 | |
EV/Sales |
0.60 | 0.33 | 0.66 | 0.64 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.13) | (0.42) | (1.01) | (1.04) | |
EV/FCF |
(0.71) | (0.29) | (0.69) | (0.70) | |
Quick Ratio |
1.01 | 1.26 | 1.20 | 1.03 | |
Current Ratio |
1.26 | 1.47 | 1.41 | 1.26 | |
Net Debt/EBITDA |
1.34 | 0.66 | 85.66 | 3.45 | |
Debt/Assets |
10.76% | 0.61% | 0.15% | 0.17% | |
Debt/Equity |
0.18 | 0.01 | 0.00 | 0.00 | |
Asset Turnover |
0.77 | 0.70 | 0.67 | 0.74 | |
Operating CF/Net income |
1.16 | 0.43 | 1.75 | 1.47 | |
Capex/Depreciation |
(0.01) | (0.02) | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
44.11% | 64.08% | 28.75% | 33.35% | |
Selling, General and Administrative Expense of Revenue |
90.36% | 168.75% | 61.06% | 81.41% | |
Intangible Assets out of Total Assets |
0.09 | 0.10 | 0.09 | 0.10 | |
Share Based Compensation of Revenue |
2.05% | 3.75% | 1.90% | 2.22% | |
Graham Net Nets |
(0.07) | 0.37 | 0.22 | 0.14 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(144.44%) | (200.58%) | (177.00%) | (176.08%) | |
Free Cash Flow Yield |
(112.79%) | (186.10%) | (113.08%) | (131.88%) | |
Revenue per Share |
2.35 | 1.63 | 2.07 | 1.85 | |
Operating CF per Share |
(1.70) | (2.75) | (0.35) | (0.82) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.71) | (2.76) | (0.35) | (0.82) | |
Cash per Share |
3.10 | 4.05 | 2.17 | 1.33 | |
Shareholders Equity per Share |
9.18 | 7.68 | 4.73 | 4.18 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.18 | 7.68 | 4.73 | 4.18 | |
Free Cash Flow |
(1.12) | (1.84) | (0.36) | (0.85) | |
Working Capital |
0.78 | 1.44 | 1.30 | 0.79 | |
Capital Expenditures |
0.00 | 0.00 | — | — | |
Net Current Asset Value |
(0.32) | 1.34 | 1.22 | 0.66 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(62.26%) | (395.76%) | (9.55%) | (30.05%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.50 | 1.01 | 1.21 | 1.43 | |
Average Payables |
1.11 | 0.66 | 0.54 | 0.65 | |
Average Inventory |
0.39 | 0.37 | 0.35 | 0.35 | |
Average Assets |
8.26 | 8.46 | 9.67 | 9.00 | |
Average Common Equity |
3.09 | 4.44 | 6.21 | 5.59 |
Columns are period end dates